Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

AI-driven synthetic data generation for accelerating hepatology research: A study of the United Network for Organ Sharing (UNOS) database
Ahn, Joseph , Noh, Yung‐Kyun , Hu, Mingzhao , Shen, Xiaotong , Kamath, Patrick S. , Shah, Vijay H. , Ahn, Joseph C , Simonetto, Douglas A , Kamath, Patrick S , Loomba, Rohit , Simonetto, Douglas A.

Hepatology | March 11, 2025 | Volume: 83 | Issue: 2 | Pages: 304-316

10.1097/hep.0000000000001299 | PMID 40067682 Get It

Background and Aims: Clinical hepatology research often faces limited data availability, underrepresentation of minority groups, and complex data-sharing regulations. Synthetic data—artificially generated patient records designed to mirror real-world distributions—offers a potential solution. We hypothesized that diffusion models, a state-of-the-art generative technique, could produce synthetic liver transplant waitlist data from the United Network for Organ Sharing database that maintains statistical fidelity, replicates clinical correlations and survival patterns, and ensures robust privacy protection. Approach and Results: Diffusion models were used to generate synthetic patient cohorts mirroring the United Network for Organ Sharing liver transplant waitlist database between the years 2019 and 2023. Statistical fidelity was assessed using maximum mean discrepancy (MMD) and Wasserstein distance, correlation analysis, and variable-level metrics. Clinical utility was evaluated by comparing transplant-free survival via Kaplan–Meier curves and the MELD score performance. Privacy was quantified using the Distance to Closest Record (DCR) and attribute disclosure risk assessments. The synthetic dataset was nearly indistinguishable from the original dataset (MMD=0.002, standardized Wasserstein distance <1.0), preserving clinically relevant correlations and survival patterns as evidenced by similar median survival times (110 vs. 101 days) and 5-year survival rates (22.2% vs. 22.8%). MELD-based 90-day mortality prediction was maintained (original AUC=0.839 vs. synthetic AUC=0.844). Privacy metrics indicated no identifiable patient matches, and mean DCR values ensured that synthetic individuals were not direct replicas of real patients. Conclusion: Artificial intelligence–generated synthetic data derived from diffusion models can faithfully replicate complex hepatology datasets, maintain key clinical signals, and ensure strong privacy safeguards. This approach can help address data scarcity, enhance model generalizability, foster multi-institutional collaboration, and accelerate progress in hepatology research.
Automated Insulin Delivery in Elderly with Type 1 Diabetes: A Prespecified Analysis of the Extension Phase
Kudva, Yogish C. , Henderson, Robert J. , Kanapka, Lauren , Weinstock, Ruth S. , Rickels, Michael R. , Janess, Kamille , Desjardins, Donna, Pattan, Vishwanath , Peleckis, Amy J. , Casu, Anna , Rizvi, Shafaq , Bzdick, Suzan, Whitaker, Keri, KAMIMOTO, JORGE L. JO, Miller, Kellee M. , Kollman, Craig, group, for the AIDE study, Kanapka, Lauren G , Rizvi, Shafaq Raza , Beck, Roy W , Rickels, Michael R , Pratley, Richard E. , Chaytor, Naomi , Beck, Roy W. , group, for the AIDE study

Diabetes Technology & Therapeutics | March 11, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1089/dia.2024.0560 | PMID 40067490 Get It

Dialysis Dependence in Standard versus Accelerated Initiation of KRT in AKI
McCoy, Ian E. , Ghamarian, Ehsan , Quenot, Jean‐Pierre , Zarbock, A., Bihorac, Azra , Khoo, Benjamin Zhi En , Gallagher, Martin , Du, Bin , Joannidis, Michael , Tolwani, Ashita , Investigators, For the STandard versus Accelerated initiation of Renal Replacement Therapy in AKI (STARRT-AKI), Guitton, Christophe , Bihari, Shailesh , Ghamarian, Ehsan , Bihorac, Azra , Khoo, Benjamin , Gallagher, Martin P , Du, Bin , Joannidis, Michael , Kashani, Kianoush B , Tolwani, Ashita , Bagshaw, Sean M , Wald, Ron , McCoy, Ian E , Liu, Kathleen D. , Kashani, Kianoush , Bagshaw, Sean M. , Investigators, For the STandard versus Accelerated initiation of Renal Replacement Therapy in AKI (STARRT-AKI)

Clinical Journal of the American Society of Nephrology | March 11, 2025 | Volume: 20 | Issue: 5 | Pages: 601-607

10.2215/cjn.0000000672 | PMID 40232884 Get It

Key Points The Standard versus Accelerated Initiation of Renal Replacement Therapy in AKI trial found that starting dialysis earlier for AKI resulted in a 74% higher risk of still receiving dialysis at 90 days. Among patients who likely would have started dialysis under usual practice, the risks of dialysis dependence were similar. This suggests much of the risk observed may have been due to starting dialysis (versus never starting) rather than starting slightly earlier. Background The Standard versus Accelerated Initiation of Renal Replacement Therapy in AKI Trial showed that among critically ill patients with AKI, an accelerated KRT initiation strategy resulted in more KRT dependence at 90 days, as compared with a standard strategy. However, it is unclear whether this difference exists among participants who likely would have been treated with KRT in usual practice. Methods Secondary analysis of the Standard versus Accelerated Initiation of Renal Replacement Therapy in AKI randomized controlled trial, analyzing participants who received more than the median number of days of KRT, which served as a proxy for high probability of requiring KRT under usual practice. Two sensitivity analyses redefined the cohort as ( 1 ) those with ≥24 hours of oliguria who received KRT and ( 2 ) those who received any KRT. Using the same statistical approach as the original trial, we calculated unadjusted relative risks with 95% confidence intervals (CIs) for the exposure of randomized KRT initiation strategy (accelerated versus standard) on the outcome of KRT dependence at 90 days among survivors. Results Among the 1184 participants who received ≥6 days of KRT (670 and 514 in the accelerated and standard arms, respectively), baseline characteristics remained balanced between treatment arms. The relative risk of KRT dependence at 90 days was attenuated and nonsignificant: 1.21 (95% CI, 0.84 to 1.78), compared with 1.74 (95% CI, 1.24 to 2.43) in the overall trial. The results were similar in sensitivity analyses. Conclusions Among patients who likely would have been treated with KRT in usual practice, there was no significant difference in 90-day KRT dependence among survivors between those randomized to the accelerated and standard KRT initiation strategies. These results suggest that the harm of long-term KRT dependence may be largely due to KRT initiation (versus never initiation) rather than earlier initiation. Clinical Trial registry name and registration number: NCT02568722.
eLife assessment: Propionyl-CoA carboxylase subunit B regulates anti-tumor T cells in a pancreatic cancer mouse model
Rogers, Laura Q. , Rogers, Laura

No container title available | March 11, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.96925.2.sa0 Get It

Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer
Chen, Li , Mansfield, Aaron S. , Lheureux, Stéphanie , O’Connor, C.J., Zamboni, Beth A., Patel, Kashish, McKee, Tawnya C., Moscow, Jeffrey A. , Zamboni, William C. , Mansfield, Aaron S , Lheureux, Stephanie , Moscow, Jeffrey A , Lucas, Andrew T.

Clinical and Translational Science | March 11, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1111/cts.70178 | PMID 40051118 Get It

ABSTRACTAnetumab ravtansine, like other ADC drugs, has high inter‐patient variability in its pharmacokinetic (PK) and pharmacodynamic (PD) outcomes, which raises concerns about whether current dosing regimens are optimal for patients. The objective of this study was to evaluate covariates, especially body habitus and the innate immune system (IIS), which may affect anetumab ravtansine PK and PD as part of two clinical trials in patients with ovarian cancer and mesothelioma. Biomarkers of Fcγ receptors(FcγR) CD64 on IIS cells, total body weight (TBW), body surface area (BSA), and other covariates, such as sex and age, were analyzed for an association with anetumab ravtansine PK. Higher FcγR CD64, TBW, and BSA were associated with higher clearance (CL) of anetumab ravtansine (p < 0.05). However, there was no relationship between TBW or BSA and FcγR CD64. Female patients had a lower anetumab ravtansine CL (0.030 ± 0.007 L/h) compared to male patients (0.042 ± 0.006 L/h) (p < 0.05). In both studies, patients with stable disease (SD) and partial response (PR) had higher anetumab ravtansine AUC0‐inf compared to patients with progressive disease (PD). Individualizing the dose of anetumab ravtansine and potentially other ADCs based only on TBW is not optimal, whereas precision dosing of an ADC based on the inclusion of novel metrics of IIS biomarkers, body habitus, and sex may be more appropriate to reduce variability in PK exposure, reduce toxicity, and improve response.
Intestinal Permeability In Vivo in Patients With Inflammatory Bowel Disease: Comparison of Active Disease and Remission
Dunleavy, Katie A. , Rypstra, Chad R, Busciglio, Irene, Eckert, Deborah J., Ryks, Michael, Omerdic, Ellie, Raffals, Laura E. , Camilleri, Michael , Eckert, Deborah, Chedid, Victor G , Camilleri, M , Dunleavy, Katie , Chedid, Victor

Inflammatory Bowel Diseases | March 11, 2025 | Volume: 31 | Issue: 9 | Pages: 2511-2520

10.1093/ibd/izaf043 | PMID 40067071 Get It

Abstract Background and Aims Inflammatory bowel disease (IBD) is associated with altered mucus and increased intestinal permeability (IP). Prior reports on permeability in IBD typically used lactulose-to-mannitol ratio (LMR). Food contamination with 12C-mannitol is a significant potential confounder in IP assessment. We aimed to compare small intestinal (SI) and colonic (COL) permeability in IBD, both active (ACT) and in remission (REM), to normal healthy volunteers (NHV). Methods Inflammatory bowel disease activity was based on Simple Endoscopic Score for Crohn’s Disease (SES-CD) and Mayo endoscopy score for ulcerative colitis (UC). We performed 24-hour IP test using 100 mg 13C-mannitol and 1000 mg lactulose with urine collected during 0-2, 2-8, and 8-24 hours. The primary endpoint was mg excretion of 13C-mannitol and lactulose during 2-24 hours reflecting SI and COL permeability. Results Among 17 CD patients, 7 were ACT (SES-CD &gt;6), and 10 REM (SES-CD 0-2). Among 20 UC patients, 10 had ACT (Mayo score 2-3), and 10 REM (Mayo score 0-1). Urinary excretions over 2-24 hours were higher for IBD than NHV: 13C-mannitol (13.8 [IQR 8.8, 18.7] NHV; 18.4 [15.6, 29.9] REM; 19.7 [13.8, 23.6] ACT, P = .003) and lactulose (1.8 [1.3, 3.1] NHV; 3.6 [2.0, 5.0] REM; 3.5 [2.0, 6.6] ACT, P = .006). There was no difference between ACT and REM for any timed urine collection. LMR at 2-24 hours (or 2-8 and 8-24 hours) were not statistically significant between the 3 groups (0.014 [0.010, 0.021] NHV; 0.016 [0.010, 0.023] REM; 0.016 [0.012, 0.038] ACT, P = .237). Conclusions Intestinal permeability is increased in IBD using validated in vivo assay relative to NHV; increased IP in IBD persists during remission.
Phase I Study of Vorinostat and Temsirolimus in Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
Stitzlein, Lea , Baig, Muhammad Usman , Chandra, Joya , McGovern, Suzanne, Paulino, Arnold C. , Ketonen, Leena , Khatua, Soumen , Zaky, Wafik , Stitzlein, Lea M , Paulino, Arnold C , Baig, Muhammad Usman

Pediatric Blood & Cancer | March 11, 2025 | Volume: 72 | Issue: 5 | Pages: No page available

10.1002/pbc.31619 | PMID 40000388 Get It

ABSTRACT Background Diffuse intrinsic pontine glioma (DIPG) carries a poor prognosis with a median survival of less than 12 months. Key molecular features include histone H3 mutation (K27M) and AKT pathway dysregulation. There is currently no curative treatment. Methods This is a Phase I study of vorinostat and temsirolimus in newly diagnosed (Stratum 1) and progressive (Stratum 2) DIPG (NCT02420613). The primary aims are to determine the safety, maximum tolerated dose (MTD), and toxicities. A modified 3 + 3 design was used to establish the MTD, where the first three patients were assigned the first dose level regardless of stratum. Stratum 1 received radiotherapy with vorinostat, followed by up to 10 cycles of vorinostat and temsirolimus. Stratum 2 received up to 12 cycles of vorinostat and temsirolimus. Vorinostat was administered at a fixed dose of 230 mg/m 2 daily on Days 1–8, and temsirolimus was administered on Days 1 and 8 at 25 mg/m 2 (Dose level 1) or 35 mg/m 2 (Dose level 2). Results Six patients were enrolled, three in each stratum. No dose‐limiting toxicity was observed, and most adverse effects were limited to Grades 1 or 2, including fatigue, myelosuppression, hyperlipidemia, hyperglycemia, elevated creatinine, nausea, vomiting, and headache. One patient experienced Grade 3 leukopenia. In the study, the MTD with acceptable toxicity was vorinostat 230 mg/m 2 and temsirolimus 35 mg/m 2 . Conclusions Overall, the combination of temsirolimus and vorinostat is well‐tolerated and safe, prompting the need for larger studies to investigate its efficacy.
Definitions, diagnosis, and management of postoperative recurrence in Crohn’s disease patients with permanent ileostomy—a systematic review and meta-analysis
Abushamma, Suha , Yadete, Tesfaye , Nero, Neil , Falloon, Katherine , Parker, Claire E. , Ahuja, Vineet, Armuzzi, Alessandro , Bemelman, Willem A. , Bruining, David H. , Feagan, Brian G. , Hart, Ailsa, Leong, Rupert W. , Narula, Neeraj , Raine, Tim , Singh, Siddharth , Sparrow, Miles , Spinelli, Antonino , Koughnett, Julie Ann Van, Solitano, Virginia , Yuan, Yuhong , Rieder, Florian , Deepak, Parakkal , Dignass, Axel , Fulmer, Clifton , Halfvarson, Jonas , Holubar, Stefan D , Ma, C , Magro, F , McCurdy, Jeffrey D , Narula, Neeraj , Panes, Julian , Raine, Tim , Regueiro, Miguel , Spinelli, Antonino , Rieder, Florian , Solitano, Virginia , Leong, Rupert W , Abreu, María T. , Ahuja, Vineet , Deepak, Parakkal , Dotan, Iris , Fulmer, Clifton G. , Hart, Ailsa , Holubar, Stefan D. , Ma, Christopher , Magro, Fernando , Panés, Julián , Regueiro, Miguel , Rogler, Gerhard , Vuyyuru, Sudheer K. , Jairath, Vipul

Journal of Crohn's and Colitis | March 11, 2025 | Volume: 19 | Issue: 4 | Pages: No page available

10.1093/ecco-jcc/jjaf041 | PMID 40066499 Get It

Abstract Background and Aims Over 10% of patients with Crohn’s disease require permanent ileostomy. We aimed to summarize the existing data on diagnosis, definitions of recurrence, and management of Crohn’s disease patients with permanent ileostomy. Methods MEDLINE, Embase, and CENTRAL databases were searched from inception to February 6, 2024. Randomized controlled trials, cohort and cross-sectional studies, and case series of more than 5 patients reporting on postoperative recurrence or the need for surgery in patients with Crohn’s disease and permanent ileostomy were included. Search results were independently screened, and full text of all titles meeting eligibility criteria was obtained. Outcomes of interest included diagnostic techniques, recurrence definitions, and management approaches. We estimated pooled rates (with 95% confidence interval [CI]) of recurrence. Results Thirty cohort studies including 2055 Crohn’s patients with permanent ileostomy were included (53% female, median age at the time of ileostomy creation 32 years, the most common reason for ileostomy was refractory disease). The postoperative recurrence rate was 27% (95% CI, 21.3–33.3, 26 studies, 451/1805 patients). Modalities for diagnosis of Crohn’s disease recurrence were symptoms (15 studies), endoscopy (4 studies), histology from endoscopic biopsies (2 studies), imaging (5 studies), and surgery (22 studies). The reported definitions of recurrence for each modality were heterogeneous. Conclusions There is a lack of standardized monitoring tools and criteria for diagnosing recurrence in patients with Crohn’s disease and permanent ileostomy. The results of this systematic review will form the basis of a global expert recommendation exercise focused on developing management standards and trial endpoints for this condition.
TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
Shah, Meera , Arber, Daniel A. , Hiwase, Devendra , Shah, Mithun V , Hiwase, Devendra , Arber, Daniel A

American Journal of Hematology | March 11, 2025 | Volume: 100 | Issue: S4 | Pages: 88-115

10.1002/ajh.27655 | PMID 40066944 Get It

ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations ( TP53 mut ) and present immense challenges due to inherent chemoresistance and poor outcomes. As TP53 mut are more common in older individuals and those with secondary/therapy‐related myeloid neoplasms (MN), their incidence is expected to increase with an aging population and rising proportion of cancer survivors. Treatments used for other MN—intensive chemotherapy, hypomethylating agents, and the BCL‐2 inhibitor venetoclax—do not improve the survival of TP53 mut MN patients meaningfully. Additionally, further development of many promising agents has been discontinued, highlighting the challenges. Widespread acknowledgment of these problems led to the recognition of TP53 mut MN as a distinct entity in the 5th edition of the World Health Organization and International Consensus Classifications. However, critical discrepancies between the two classifications may lead to under‐ or overestimation of the prognostic risk. Here, we review recent advances in the biology, diagnosis, and treatment of TP53 mut MN. The development of TP53 mut MN is positioned at the intersection of age, hereditary predisposition, and anti‐cancer therapies. Precursor TP53 mut clones can be detected years prior to the eventual leukemic transformation—raising the possibility of early intervention. We discuss the two classification systems and the bearing of the discrepancies between the two on timely and effective management. We provide novel evidence in the areas of discrepancies. Finally, we review the current therapeutic landscape and the obvious limitations of the currently used therapies.
Determinants of late metastases in renal cell carcinoma
Kapur, Payal , Zhong, Hua , Christie, Alana , Xu, Haitao , Cai, Qi , Araj, Ellen, Kim, David , Miyata, Jeffrey , Tcheuyap, Vanina Toffessi , Ball, Colleen T. , Thiel, David D. , Parker, Alexander S. , Antwi, Samuel O. , Leibovich, Bradley C. , Cheville, John C. , Tcheuyap, Vanina T , Leibovich, Bradley C , Modrusan, Zora , Brugarolas, James , Antwi, Samuel O , Kapur, Payal , Kim, David , Modrušan, Zora , Brugarolas, James

JNCI: Journal of the National Cancer Institute | March 11, 2025 | Volume: 117 | Issue: 7 | Pages: 1387-1400

10.1093/jnci/djaf060 | PMID 40065697 Get It

Abstract Background The mechanisms underlying metastatic latency in renal cell carcinoma (RCC) remain poorly understood. Methods This study evaluated 2 large independent cohorts for differences in tumor biology between patients who developed metastases early (≤1 year after nephrectomy) and those with late onset (&gt;3 years). Results In the discovery cohort (n = 161), late metastatic RCC was associated with clear cell histology (88.9% vs 78.7%), lower pathological stage (pT1-2; 40.3% vs 18.0%), and favorable histopathological features including low grade (40.0% vs 2.3%), less sarcomatoid (5.6% vs 21.8%), and reduced necrosis (37.7% vs 78.3%; all P &lt; .02). Late metastatic RCC tumors exhibited increased angiogenesis (63.5% vs 19.4%) and reduced inflammation (78.8% vs 50.0%; all P &lt; .02) profiles. Genomic driver analyses revealed comparable rates of PBRM1 and SETD2 loss in late and early metastatic RCC, while BAP1 loss was significantly less common in late metastatic RCC (7.5% vs 27.1%; P &lt; .02). In multivariable models, BAP1/PBRM1/SETD2 status and tumor necrosis emerged as key discriminators of late metastatic RCCs. These findings were confirmed in the second cohort (n = 307). Late metastatic RCC was enriched for fatty acid oxidation and angiogenesis pathways, supporting a less aggressive phenotype. This was further evidenced by a lower engraftment rate in murine models (0% vs 36.5%; P &lt; .001) and significantly longer overall survival from the time of metastasis (median survival doubled, P &lt; .001). Interestingly, late metastatic RCC shared genomic and phenotypic features with RCC that metastasizes to the pancreas, suggesting a common underlying biology influencing both metastatic latency and pancreatic tropism. Conclusions Overall, these findings advocate for recognition of late metastatic RCC because of its distinct biology and improved prognosis.